IL149251A0 - Diagnosis and treatment of cardiovascular conditions - Google Patents

Diagnosis and treatment of cardiovascular conditions

Info

Publication number
IL149251A0
IL149251A0 IL14925101A IL14925101A IL149251A0 IL 149251 A0 IL149251 A0 IL 149251A0 IL 14925101 A IL14925101 A IL 14925101A IL 14925101 A IL14925101 A IL 14925101A IL 149251 A0 IL149251 A0 IL 149251A0
Authority
IL
Israel
Prior art keywords
diagnosis
treatment
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
IL14925101A
Other languages
English (en)
Original Assignee
Brigham & Womens Hospital
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Pfizer filed Critical Brigham & Womens Hospital
Publication of IL149251A0 publication Critical patent/IL149251A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14925101A 2000-08-22 2001-08-21 Diagnosis and treatment of cardiovascular conditions IL149251A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22715900P 2000-08-22 2000-08-22
PCT/US2001/026089 WO2002016416A2 (en) 2000-08-22 2001-08-21 Diagnosis and treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
IL149251A0 true IL149251A0 (en) 2002-11-10

Family

ID=22852000

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14925101A IL149251A0 (en) 2000-08-22 2001-08-21 Diagnosis and treatment of cardiovascular conditions

Country Status (9)

Country Link
US (1) US20020115081A1 (xx)
EP (1) EP1311547A2 (xx)
JP (1) JP2004506443A (xx)
AU (1) AU8513901A (xx)
BR (1) BR0107157A (xx)
CA (1) CA2388061A1 (xx)
IL (1) IL149251A0 (xx)
RU (1) RU2002110275A (xx)
WO (1) WO2002016416A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US6640135B1 (en) * 2000-04-06 2003-10-28 Cardiac Pacemakers, Inc. Apparatus and method for spatially and temporally distributing cardiac electrical stimulation
WO2001094420A1 (en) * 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6628988B2 (en) * 2001-04-27 2003-09-30 Cardiac Pacemakers, Inc. Apparatus and method for reversal of myocardial remodeling with electrical stimulation
US6973349B2 (en) 2001-12-05 2005-12-06 Cardiac Pacemakers, Inc. Method and apparatus for minimizing post-infarct ventricular remodeling
US6915160B2 (en) * 2002-02-08 2005-07-05 Cardiac Pacemakers, Inc. Dynamically optimized multisite cardiac resynchronization device
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
US6965797B2 (en) * 2002-09-13 2005-11-15 Cardiac Pacemakers, Inc. Method and apparatus for assessing and treating myocardial wall stress
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2005075646A1 (ja) * 2004-02-03 2005-08-18 Kurume University ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
WO2006078853A2 (en) * 2005-01-20 2006-07-27 University Of Rochester Thioredoxin interacting protein (txnip) as regulator of vascular function
US9050393B2 (en) * 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US7366567B2 (en) * 2005-03-23 2008-04-29 Cardiac Pacemakers, Inc. Method for treating myocardial infarction
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
EP2482078B1 (en) 2006-05-01 2016-02-03 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
EP2686689B1 (en) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US20150018384A1 (en) * 2012-03-09 2015-01-15 Fibrogen, Inc. Treatment for high cholesterol
IN2015DN01767A (xx) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
CA2884121C (en) * 2012-09-07 2021-10-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
FR3100714A1 (fr) * 2019-09-12 2021-03-19 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Argon associé à une thrombectomie en cas d’accident vasculaire cérébral ischémique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217899A (en) * 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2002524049A (ja) * 1998-08-07 2002-08-06 オニックス ファーマシューティカルズ，インコーポレイティド Ｃｈｐポリペプチド、ｐａｋ６５のリガンド
JP2003518913A (ja) * 1998-12-11 2003-06-17 インサイト・ファーマスーティカルズ・インコーポレイテッド ニューロン関連タンパク質
WO2000052022A1 (en) * 1999-03-01 2000-09-08 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
US20030180728A1 (en) * 2002-03-22 2003-09-25 Kovacs Karl F. Human BCU399 gene, polypeptide, and uses

Also Published As

Publication number Publication date
WO2002016416A3 (en) 2003-03-13
AU8513901A (en) 2002-03-04
EP1311547A2 (en) 2003-05-21
US20020115081A1 (en) 2002-08-22
WO2002016416A2 (en) 2002-02-28
CA2388061A1 (en) 2002-02-28
BR0107157A (pt) 2002-07-16
RU2002110275A (ru) 2004-03-27
JP2004506443A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
GB2368794B (en) Prevention and treatment of amyloidogenic disease
AU1166502A (en) Human ect2 and methods of use
GB9903841D0 (en) Diagnosis and treatment of cancer
HUP0201205A2 (en) Prevention and treatment of amyloidogenic disease
IL159816A0 (en) In-vivo method and device for improving diastolic function of the left ventricle
IL158532A0 (en) Treatment and diagnosis of macrophage mediated disease
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
HK1043546A1 (zh) 採用異黃酮類化合物治療心血管疾病和骨疾病
EP1335736A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEART CIRCULAR DISEASES
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
EP1451138A4 (en) METHOD FOR REVERTING AND PREVENTING THE PROCESS OF CARDIOVASCULAR DISEASES
GB2360453B (en) Treatment of skin conditions
GB2381272B (en) Diagnosis and treatment of atherosclerosis
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
GB0120009D0 (en) Cause and effect diagnosis
EP1443953A4 (en) IDENTIFICATION AND TREATMENT OF INTRAVASCULAR LESIONS
EP1303281A4 (en) METHODS OF TREATMENT
EP1392460A4 (en) AMINOSILANOL HYDROFLUORIDES AND THEIR USE
GB0024728D0 (en) Hypertension diagnosis and treatment
GB0030866D0 (en) Treatment and prevention of disease
GB0016197D0 (en) Treatment and prevention of disease